Treatment of Patients With Antiphospholipid Antibodies During Pregnancy

ABSTRACT: Most authors agree upon the causal association between antiphosholipid antibodies [lupus anticoagulant (LAC) and/or anticardiolipin antibodies] and adverse pregnancy outcome. Placental insufficiency, caused by thrombosis, infarction and maldevelopment, is thought to be the main cause of fetal loss in patients with LAC. Therapy given thus far to prevent fetal loss can be divided into (1) immunosuppression by corticosteroids, azathioprine, or intravenous gamma globulin (IVGG), (2) anti‐aggregants to overcome imbalance of thromboxane/prostacycline production in patients with LAC, and (3) anticoagulants to neutralize the possible impairment of clotting inhibitor systems. Different therapeutic success rates have been reported by various authors who used the same combination of therapy. We report the results of different therapy regimens in 154 pregnancies in 31 women with LAC. These patients suffered from SLE with LAC or from APLA syndrome and experienced either recurrent miscarriages or thromboembolic phenomena in the past. With no therapy there were seven (6.8%) live births and 95 (93.2%) failures. Various combinations of corticosteroids, anti‐aggregants and anticoagulants were used for treatment. Of 52 treated pregnancies, 27 (51.9%) were successful. Sixteen (69.1%) of 23 pregnancies treated by all three modalities ended in live births. Four of these successful pregnancies occurred after failure of treatment by prednisone and anti‐aggregants only. In order to minimize osteoporosis caused by the combination of steroids and heparin, we have used warfarin in the second trimester and have lately substituted low molecular weight heparin for heparin. In the absence of a therapeutic schedule predicated on a large prospective study, therapy during pregnancy in patients having LAC should be individualized according to their obstetric and medical history. Anticoagulants are indicated in patients who have suffered from thromboembolic phenomena and could be tried after failure of steroids and anti‐aggregants.

[1]  Z. Blumenfeld,et al.  Low Molecular Weight Heparin (Clexan) — A Promising Treatment in Women With Recurrent Abortions in SLE and Antiphospholipid Antibody Syndrome , 1992 .

[2]  D. Balaban,et al.  Repeated fetal losses associated with antiphospholipid antibodies: a collaborative randomized trial comparing prednisone with low-dose heparin treatment. , 1992, American journal of obstetrics and gynecology.

[3]  E. Salzman.  Low-molecular-weight heparin and other new antithrombotic drugs. , 1992, The New England journal of medicine.

[4]  Hunt,et al.  A Phospholipid-β2-Glycoprotein I Complex Is an Antigen for Anticardiolipin Antibodies Occurring in Autoimmune Disease But Not with Infection , 1992, Lupus.

[5]  J. Maclouf,et al.  Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. , 1991, Blood.

[6]  R. Derksen,et al.  Histopathological findings in placentae from patients with intra-uterine fetal death and anti-phospholipid antibodies. , 1991, European journal of obstetrics, gynecology, and reproductive biology.

[7]  F. Parazzini,et al.  Antiphospholipid Antibodies and Recurrent Abortion , 1991, Obstetrics and gynecology.

[8]  Y. Shoenfeld,et al.  Induction of anti-phospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[9]  H. Brown.  Antiphospholipid Antibodies and Recurrent Pregnancy Loss , 1991, Clinical obstetrics and gynecology.

[10]  N. Rote,et al.  Antiphospholipid antibodies and recurrent pregnancy loss: correlation between the activated partial thromboplastin time and antibodies against phosphatidylserine and cardiolipin. , 1990, American journal of obstetrics and gynecology.

[11]  M. Cullen,et al.  Recurrent adverse pregnancy outcome and antiphospholipid antibodies. , 1990, American journal of obstetrics and gynecology.

[12]  K. Kalunian,et al.  Heparin therapy for pregnant women with lupus anticoagulant or anticardiolipin antibodies , 1990, Obstetrics and gynecology.

[13]  J. Balasch,et al.  Antiphospholipid antibodies in unselected patients with repeated abortion. , 1990, Human reproduction.

[14]  D. Alarcón-Segovia,et al.  Antiphospholipid arterial vasculopathy. , 1989, The Journal of rheumatology.

[15]  M. Druzin,et al.  Prednisone does not prevent recurrent fetal death in women with antiphospholipid antibody. , 1989, American journal of obstetrics and gynecology.

[16]  G. Pardi,et al.  Effect of prednisone and heparin treatment in 14 patients with poor reproductive efficiency related to lupus anticoagulant. , 1989, Fetal therapy.

[17]  M. Sheridan-Pereira,et al.  NEONATAL AORTIC THROMBOSIS ASSOCIATED WITH THE LUPUS ANTICOAGULANT , 1988, Obstetrics and gynecology.

[18]  G. Liggins,et al.  Role of Lupus Anticoagulant and Autoimmunity in Recurrent Pregnancy Loss , 1988 .

[19]  M. Modan,et al.  Detection and Quantitative Evaluation of Lupus Circulating Anticoagulant Activity , 1987, Thrombosis and Haemostasis.

[20]  C. Soria,et al.  Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant. , 1986, The New England journal of medicine.

[21]  G. Liggins,et al.  FETAL SURVIVAL AFTER PREDNISONE SUPPRESSION OF MATERNAL LUPUS-ANTICOAGULANT , 1983, The Lancet.